Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension.

[1]  D. Borderie,et al.  N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? , 2008, Annals of the rheumatic diseases.

[2]  P. Thomas,et al.  Biomarkers in pulmonary hypertension , 2008, European Respiratory Journal.

[3]  G. Giannakoulas,et al.  Limitations of the findings regarding the relationship between N-terminal pro-brain natriuretic peptide and systemic sclerosis-related pulmonary arterial hypertension: comment on the article by Allanore et al. , 2008, Arthritis and rheumatism.

[4]  G. Lippi,et al.  N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH , 2008, Rheumatology International.

[5]  G. Giannakoulas,et al.  N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension , 2008, Clinical Rheumatology.

[6]  A. Maisel,et al.  Natriuretic peptides. , 2007, Journal of the American College of Cardiology.

[7]  G. Giannakoulas,et al.  Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy , 2007, Heart and Vessels.

[8]  G. Giannakoulas,et al.  Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2007, International Journal of Cardiology.

[9]  J. Marcus,et al.  Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. , 2007, The Annals of thoracic surgery.

[10]  E. Terpos,et al.  Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. , 2007, Haematologica.

[11]  J. Foster,et al.  NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension , 2007, European Respiratory Journal.

[12]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[13]  B. Hartmann,et al.  N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. , 2007, Chest.

[14]  Z. Jing,et al.  Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. , 2006, Journal of the American College of Cardiology.

[15]  M. Kurzyna,et al.  Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis , 2006, Clinical Rheumatology.

[16]  G. Lippi,et al.  Evaluation of cardiac laboratory markers in patients with systemic sclerosis. , 2006, Clinical biochemistry.

[17]  C. Denton,et al.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[18]  A. Torbicki,et al.  Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.

[19]  M. Scherillo,et al.  Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. , 2005, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[20]  M. Humbert,et al.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.

[21]  G. Louridas,et al.  N-Terminal Pro-Brain Natriuretic Peptide Levels Are Elevated in Patients with Acute Ischemic Stroke , 2005, Angiology.

[22]  D. Duboc,et al.  Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. , 2005, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[23]  M. Vogeser,et al.  Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. , 2005, Chest.

[24]  S. Rantapää-Dahlqvist,et al.  Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. , 2005, Chest.

[25]  J. Hollander,et al.  Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. , 2005, Annals of emergency medicine.

[26]  R. Souza,et al.  Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension , 2005, Current medical research and opinion.

[27]  R. Ekman,et al.  Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. , 2005, Rheumatology.

[28]  H. Bada,et al.  Brain-Type Natriuretic Peptide in the Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn , 2004, Pediatrics.

[29]  J. Boldt,et al.  Natriuretic peptide system: physiology and clinical utility , 2004, Current opinion in critical care.

[30]  P. Timms,et al.  Natriuretic peptides, respiratory disease, and the right heart. , 2004, Chest.

[31]  L. Wallentin,et al.  Natriuretic peptides in unstable coronary artery disease. , 2004, European heart journal.

[32]  M. Vogeser,et al.  Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. , 2004, American journal of respiratory and critical care medicine.

[33]  M. Emdin,et al.  Right ventricular overload and cardiovascular neuroendocrine derangement in systemic sclerosis , 2004 .

[34]  T. Mueller,et al.  Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[35]  James D. Thomas,et al.  Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. , 2004, Journal of the American College of Cardiology.

[36]  G. Baxter,et al.  Autocrine and paracrine actions of natriuretic peptides in the heart. , 2004, Pharmacology & therapeutics.

[37]  D. Borderie,et al.  N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. , 2003, Arthritis and rheumatism.

[38]  Stephen J. Huang,et al.  The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients* , 2003, Critical care medicine.

[39]  J. Kline,et al.  Elevated brain natriuretic peptide in septic patients without heart failure. , 2003, Annals of emergency medicine.

[40]  A. Holmes,et al.  Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2003, Respiratory medicine.

[41]  C. Denton,et al.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.

[42]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[43]  H. Ruskoaho.  Cardiac hormones as diagnostic tools in heart failure. , 2003, Endocrine reviews.

[44]  M. Sutton,et al.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[45]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  S. Kimmel,et al.  Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.

[47]  S. Anker,et al.  Neurohormonal Activation and the Chronic Heart Failure Syndrome in Adults With Congenital Heart Disease , 2002, Circulation.

[48]  Takashi Sugamori,et al.  High Plasma Brain Natriuretic Polypeptide Level as a Marker of Risk for Thromboembolism in Patients With Nonvalvular Atrial Fibrillation , 2002, Stroke.

[49]  A. Maggioni,et al.  Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure , 2002, Clinical chemistry and laboratory medicine.

[50]  P. Mathisen,et al.  Natriuretic peptides in patients with aortic stenosis. , 2001, American heart journal.

[51]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[52]  Kenji Nakamura,et al.  Cardiac fibrosis in mice lacking brain natriuretic peptide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[53]  H. Inoue,et al.  Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. , 1999, American journal of hypertension.

[54]  R. Levin,et al.  Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. , 1998, American heart journal.

[55]  H. Hense,et al.  Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. , 1997, American heart journal.

[56]  R. Doughty,et al.  Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairment , 1997, Clinical endocrinology.

[57]  H. Aken,et al.  Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage , 1997, The Lancet.

[58]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[59]  M. Yacoub,et al.  Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. , 1994, British heart journal.

[60]  C. Black,et al.  Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1994, The Journal of rheumatology.

[61]  N. Hill,et al.  Downregulation of pulmonary atrial natriuretic peptide receptors in rats exposed to chronic hypoxia. , 1994, Journal of applied physiology.

[62]  L. Blendis,et al.  Pathophysiology of Sodium Retention and Ascites Formation in Cirrhosis: Role of Atrial Natriuretic Factor , 1994, Seminars in liver disease.

[63]  N. Markandu,et al.  Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. , 1992, Clinical science.

[64]  K. Chien,et al.  Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. , 1990, The Journal of biological chemistry.

[65]  Naoto Minamino,et al.  A new natriuretic peptide in porcine brain , 1988, Nature.

[66]  D. Borderie,et al.  High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. , 2008, Arthritis and rheumatism.

[67]  Shinichi Sato,et al.  Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports , 2005, Rheumatology International.

[68]  Y. Hasin,et al.  Cardiovascular Effects of Natriuretic Peptides and Their Interrelation with Endothelin-1 , 2004, Cardiovascular Drugs and Therapy.

[69]  U. Janssens,et al.  Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. , 2004, American heart journal.

[70]  K. Takishima,et al.  Changes in atrial natriuretic peptide and brain natriuretic peptide associated with hypobaric hypoxia-induced pulmonary hypertension in rats , 2001, Virchows Archiv.

[71]  S. Kuribayashi,et al.  Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. , 1998, Journal of the American College of Cardiology.

[72]  H. Imura,et al.  Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy. An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies. , 1993, The American journal of pathology.

[73]  D. Mccrory,et al.  Evidence-based Clinical Practice Guidelines : Accp * Pulmonary Arterial Hypertension Screening, Early Detection, and Diagnosis Of , 2022 .